[1]钟石古.喜炎平联合奥司他韦治疗流感病毒性肺炎的临床分析[J].医学信息,2025,38(04):107-111.[doi:10.3969/j.issn.1006-1959.2025.04.018]
　ZHONG Shigu.Clinical Analysis of Xiyanping Combined with Oseltamivir in the Treatment of Influenza Virus Pneumonia[J].Journal of Medical Information,2025,38(04):107-111.[doi:10.3969/j.issn.1006-1959.2025.04.018]
点击复制

喜炎平联合奥司他韦治疗流感病毒性肺炎的临床分析()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
38卷
期数:
2025年04期
页码:
107-111
栏目:
论著
出版日期:
2025-02-15

文章信息/Info

Title:
Clinical Analysis of Xiyanping Combined with Oseltamivir in the Treatment of Influenza Virus Pneumonia
文章编号:
1006-1959（2025）04-0107-05
作者:
钟石古
安远县人民医院儿科，江西 安远 342100
Author(s):
ZHONG Shigu
Department of Pediatrics, Anyuan County People’s Hospital, Anyuan 342100, Jiangxi, China
关键词:
喜炎平; 奥司他韦; 流感病毒性肺
Keywords:
Xiyanping;  Oseltamivir;  Influenza virus pneumonia
分类号:
R563.1
DOI:
10.3969/j.issn.1006-1959.2025.04.018
文献标志码:
A
摘要:
目的 探讨喜炎平联合奥司他韦治疗流感病毒性肺炎患者的临床效果。方法 选取2021年12月-2023年11月安远县人民医院收治的78例流感病毒性肺炎患者为研究对象，按照随机数字表法将其分为对照组和观察组，每组39例。对照组口服奥司他韦治疗，观察组在对照组基础上应用喜炎平注射液静脉滴注给药治疗。比较两组治疗效果、不良反应（精神差、恶心呕吐、腹痛腹泻、皮疹）发生率、临床症状转归时间（发热、乏力、憋喘、气促、湿罗音消失时间及核酸转阴时间）、炎性因子水平[白细胞介素-1β（IL-1β）、白细胞介素-6（IL-6）、肿瘤坏死因子-α（TNF-α）、高敏C反应蛋白（hs-CRP）]、肺功能水平[用力肺活量（FVC）、第1秒最大呼气量（FEV1）、最高呼气流速（PEF）、用力呼气25%流速（MEF25）]。结果 观察组治疗总有效率为97.44%，高于对照组治疗总有效率的79.49%（P＜0.05）。观察组不良反应发生率为10.26%，与对照组的12.82%比较，差异无统计学意义（P＞0.05）。观察组发热、乏力、憋喘、气促、湿罗音、核酸转阴等临床症状转归时间均低于对照组（P＜0.05）。观察组炎性因子水平低于对照组（P＜0.05）。观察组肺功能水平高于对照组（P＜0.05）。结论 喜炎平联合奥司他韦治疗流感病毒性肺炎患者的临床效果确切，能够快速缓解患者临床症状，减轻炎性因子水平，提高患者肺功能，值得临床应用。
Abstract:
Objective To investigate the clinical effect of Xiyanping combined with oseltamivir in the treatment of patients with influenza virus pneumonia. Methods A total of 78 patients with influenza virus pneumonia admitted to Anyuan County People’s Hospital from December 2021 to November 2023 were selected as the research objects. According to the random number table method, they were divided into control group and observation group, with 39 patients in each group. The control group was treated with oral oseltamivir, and the observation group was treated with Xiyanping injection intravenous drip on the basis of the control group. The treatment effect, incidence of adverse reactions (poor spirit, nausea and vomiting, abdominal pain and diarrhea, rash), clinical symptom outcome time (fever, fatigue, asthma, shortness of breath, wet rale disappearance time and nucleic acid negative conversion time), inflammatory factor levels [interleukin-1β (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), high-sensitivity C-reactive protein (hs-CRP)], lung function levels [forced vital capacity (FVC), the forced expiratory volume in the first second (FEV1), peak expiratory flow (PEF), maximum expiratory flow rate at 25% (MEF25)] were compared between the two groups. Results The total effective rate of treatment in the observation group was 97.44%, which was higher than 79.49% in the control group (P<0.05). The incidence of adverse reactions in the observation group was 10.26%, which was compared with 12.82% in the control group, the difference was not statistically significant (P>0.05). The time of clinical symptoms such as fever, fatigue, suffocation, shortness of breath, wet rales and nucleic acid negative conversion in the observation group were lower than those in the control group (P<0.05). The level of inflammatory factors in the observation group was lower than that in the control group (P<0.05). The level of lung function in the observation group was higher than that in the control group (P<0.05). Conclusion Xiyanping combined with oseltamivir has a definite clinical effect in the treatment of patients with influenza virus pneumonia, which can quickly relieve the clinical symptoms, reduce the level of inflammatory factors, and improve the lung function of patients. It is worthy of clinical application.

参考文献/References:

[1]高萃,李亚梅,贺金娥,等.喜炎平注射液联合更昔洛韦对病毒性肺炎患儿的疗效及肺功能指标和血清IL-6、TNF-α水平的影响[J].现代生物医学进展,2018,18(24):4778-4781.[2]田野,孙丽平,徐炎,等.小儿细菌性肺炎2500例临床诊治分析[J].吉林中医药,2019,39(12):1541-1544,1549.[3]王勇,王臻颉.喜炎平联合阿奇霉素序贯治疗小儿支原体肺炎的疗效及对微炎症状态和免疫指标的影响[J].中南医学科学杂志,2022,50(5):740-743.[4]徐升扬,李威,詹浩欣,等.喜炎平雾化吸入给药治疗小儿肺炎的临床应用分析[J].中国临床药理学杂志,2021,37(12):1596-1598,1602.[5]陈磊,高志姝,高艳.喜炎平联合阿奇霉素序贯治疗小儿支原体肺炎的疗效及对外周血Th1/Th2表达和肺功能的影响[J].中国妇幼保健,2018,33(2):366-369.[6]火统武,杨威虎.中药注射剂喜炎平对小儿支气管肺炎的效果及对小儿肺功能的影响[J].新中医,2020,52(1):146-149.[7]李志勇,孙发鑫,许晓蒙,等.中药注射剂喜炎平对阿奇霉素组织分布的影响[J].烟台大学学报(自然科学与工程版),2022,35(1):48-54.[8]黄蕊,翟英辰,陈煜,等.奥司他韦对肺炎幼鼠ACE2/Ang(1-7)/Mas受体轴及肺损伤的影响[J].西部医学,2023,35(4):495-500.[9]彭平,张秀江,张宏生,等.奥司他韦联合小柴胡颗粒治疗病毒性肺炎的临床观察[J].中国中医急症,2022,31(9):1408-1411.[10]许斌,任春梅,范贵荣,等.奥司他韦对流感病毒肺炎模型幼鼠的治疗效果及其对血清免疫球蛋白水平的影响[J].重庆医学,2021,50(1):17-21.[11]陈永宏,余海燕,向江琳,等.奥司他韦对成人急性重症病毒性肺炎患者IL-1β、IL-6、TNF-α及免疫功能的影响[J].内蒙古医科大学学报,2020,42(3):307-310.[12]张晓伟,蒋荣猛,李玉玲.帕拉米韦与奥司他韦对流感病毒肺炎患者的疗效及安全性分析[J].中华肺部疾病杂志(电子版),2019,12(5):606-608.[13]陈圣洁,戴兰芬,李丹丹,等.帕拉米韦与奥司他韦治疗儿童流感病毒肺炎的成本-效果分析[J].中国医药,2019,14(2):215-218.[14]连玉菲,刘洪涛,高海祥,等.奥司他韦联合痰热清注射液治疗小儿病毒性肺炎的效果及安全性[J].解放军医药杂志,2018,30(12):48-52.[15]袁冕,杨彦环.磷酸奥司他韦颗粒治疗儿童病毒性肺炎的疗效观察[J].中国医院用药评价与分析,2018,18(8):1043-1044,1047.[16]栾相佳,姚晓燕,李萌,等.防风通圣颗粒联合奥司他韦治疗普通型病毒性肺炎的临床研究[J].现代药物与临床,2022,37(11):2534-2538.[17]俞泽伟,周优丽,褚亚苏.小儿热速清颗粒联合磷酸奥司他韦治疗儿童甲型流感病毒肺炎临床研究[J].新中医,2022,54(4):114-117.[18]沈晓飞,吴莉城,李小红.华盖散加减联合奥司他韦治疗小儿流感病毒性肺炎风寒闭肺证临床研究[J].新中医,2021,53(12):27-31.[19]吉亚芬,郑晓璐,罗冷.莲必治注射液联合奥司他韦治疗病毒性肺炎的临床研究[J].现代药物与临床,2021,36(9):1862-1865.[20]李振华,张华,陈建丽,等.帕拉米韦与奥司他韦治疗流感病毒性肺炎的效果[J].中华医院感染学杂志,2021,31(24):3717-3721.

相似文献/References:

[1]张小华,敏 峰,张玲丽.喜炎平联合单磷酸阿糖腺苷治疗小儿手足口病的 效果及安全性[J].医学信息,2019,32(15):157.[doi:10.3969/j.issn.1006-1959.2019.15.052]
　ZHANG Xiao-hua,MIN Feng,ZHANG Ling-li.Application Effect and Safety of Xiyanping Combined with Adenosine Monophosphate in the Treatment of Hand,Foot and Mouth Disease in Children[J].Journal of Medical Information,2019,32(04):157.[doi:10.3969/j.issn.1006-1959.2019.15.052]
[2]冯宏达.喜炎平联合利巴韦林治疗小儿手足口病的疗效[J].医学信息,2021,34(09):156.[doi:10.3969/j.issn.1006-1959.2021.09.042]
　FENG Hong-da.The Effect of Xiyanping Combined with Ribavirin in the Treatment of Hand, Foot and Mouth Disease in Children[J].Journal of Medical Information,2021,34(04):156.[doi:10.3969/j.issn.1006-1959.2021.09.042]

更新日期/Last Update: 1900-01-01